Author

Audrey Gill

Denali Therapeutics (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Alicia A. Nugent· 1 shared Amy W-S Leung· 1 shared Anna I. BakardjieviD· 1 shared Anthony A. EstradaiD· 1 shared Bahram Memarzadeh· 1 shared Chi‐Lu Chiu· 1 shared Connie HaiD· 1 shared Elysia Roche· 1 shared

Activity by Year

2023-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperNeuroscience

Alicia A. Nugent

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

DNL343 is an investigational CNS penetrant eIF2B activator that prevents and reverses the effects of neurodegeneration caused by the Integrated Stress Response

Ernie Yulyaningsih, Jung H. Suh, Melania H. Fanok, Roni Chau, Hilda O. Solanoy, Ryan Takahashi, Anna I. Bakardjiev, Isabel A. Becerra, N. Butch Benitez, Chi‐Lu Chiu, Sonnet S. Davis, William E. Dowdle, Timothy Earr, Anthony A. Estrada, Audrey Gill, , Pascal E. Sanchez

DNL343 reduces neurodegeneration in mouse models by inhibiting the integrated stress response and normalizing dysregulated biomarkers, with potential clinical relevance for vanishing white matter disease.

eLife · Nov 14, 2023Peer-reviewedNeuroscience